Antitumor efficacy of combination therapy with sequential RFA and recombinant vaccine.

<p>MC38-CEA⁺ cells were transplanted on day 0 on the right flank of CEA-Tg mice (<i>n</i> = 25–29/group). MC38-CEA⁺ tumors received sham or low-dose RFA (10–30 s at 70°C) on day 12 (dotted line), followed by high-dose ablative RFA (30–300 s at 70°C) on day 15 (solid line). Vaccinated mice received rMVA-CEA/TRICOM s.c. on day 4 and rF-CEA/TRICOM on day 11 and every 7 days thereafter, alone or in combination with sequential RFA. <b>A</b> depicts tumor growth. Data represent tumor volume ± S.E.M. in individual animals. Asterisks denote statistically significant differences among treatment groups (<i>P<</i>0.0001, 1-way ANOVA with Tukey’s multiple comparison test).